{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:09Z","timestamp":1792206369565,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113310","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:28:46Z","timestamp":1693225726000},"page":"113310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Upfront liquid next-generation sequencing in treatment-na\u00efve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system"],"prefix":"10.1016","volume":"193","author":[{"given":"Ching-Yao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-5067","authenticated-orcid":false,"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-3470","authenticated-orcid":false,"given":"Wei-Yu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Chi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-0733","authenticated-orcid":false,"given":"Chia-Lin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsiu","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-689X","authenticated-orcid":false,"given":"Shang-Gin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3350-9140","authenticated-orcid":false,"given":"Yen-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-9181","authenticated-orcid":false,"given":"Suyog","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113310_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev-med-051718-013524","article-title":"Precision management of advanced non-small cell lung cancer","volume":"71","author":"Yang","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ejca.2023.113310_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib3","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib6","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib13","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113310_bib15","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1200\/JCO.2021.39.15_suppl.9021","article-title":"Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp)","volume":"39","author":"Le","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib17","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2023.113310_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2022.10.021","article-title":"Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia","volume":"18","author":"Mitsudomi","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib20","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The international association for the study of lung cancer global survey on molecular testing in lung cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","article-title":"Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network","volume":"166","author":"Robert","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.113310_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/s12885-020-07240-2","article-title":"Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients","volume":"20","author":"Schluckebier","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113310_bib23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","article-title":"Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States","volume":"24","author":"Zou","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ejca.2023.113310_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: ten years of next-generation sequencing technologies","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ejca.2023.113310_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamaoncol.2018.4304","article-title":"Plasma vs tissue next-generation sequencing in non-small cell lung cancer-either, both, or neither?","volume":"5","author":"Gyawali","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib26","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/s41379-021-00880-0","article-title":"Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas","volume":"34","author":"Lin","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2023.113310_bib27","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113310_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41571-020-0423-x","article-title":"Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice","volume":"18","author":"Aggarwal","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib29","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1878-0261.12727","article-title":"Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy","volume":"14","author":"Chan","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib30","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/PO.20.00241","article-title":"Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer","volume":"5","author":"Palmero","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib34","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113310_bib35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4143\/crt.2019.305","article-title":"Detection of targetable genetic alterations in Korean lung cancer patients: a comparison study of single-gene assays and targeted next-generation sequencing","volume":"52","author":"Park","year":"2020","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2023.113310_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2022.01.009","article-title":"A pilot of blood-first diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer","volume":"165","author":"Cui","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.113310_bib37","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/PO.21.00029","article-title":"Plasma cfDNA genotyping in hospitalized patients with suspected metastatic NSCLC","volume":"5","author":"Cheng","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib38","first-page":"100301","article-title":"Plasma genotyping at the time of diagnostic tissue biopsy decreases time-to-treatment in patients with advanced NSCLC-results from a prospective pilot study","volume":"3","author":"Thompson","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ejca.2023.113310_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2022.05.012","article-title":"Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients","volume":"171","author":"Cui","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113310_bib40","unstructured":"Food and Drug Adminstration; 2022. Guardant360 CDx P200010\/S008. \u3008https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/guardant360-cdx-p200010s008\u3009. [Accessed 23rd October 2022]."},{"key":"10.1016\/j.ejca.2023.113310_bib41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113310_bib42","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1200\/JCO.2023.41.16_suppl.9019","article-title":"LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer","volume":"41","author":"Curcio","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib43","article-title":"Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan","volume":"10","author":"Hsu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2023.113310_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.912801","article-title":"Liquid first is \"solid\" in naive non-small cell lung cancer patients: faster turnaround time with high concordance to solid next-generation sequencing","volume":"12","author":"Sehayek","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.113310_bib45","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2023.113310_bib46","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923004124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923004124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:04Z","timestamp":1760733724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923004124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":46,"alternative-id":["S0959804923004124"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113310","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upfront liquid next-generation sequencing in treatment-na\u00efve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113310"}}